Pharmexcil appoints Bhavin Mukund Mehta as Vice Chairman
Mehta is an industry veteran with over 25 years of experience in the pharmaceutical industry
Mehta is an industry veteran with over 25 years of experience in the pharmaceutical industry
Fourth-quarter 2024 revenues totaled $17.8 billion, an increase of $3.2 billion
Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME)
It will bring together renowned global experts in the field to discuss groundbreaking advances in biomaterials and their clinical applications
The company will showcase groundbreaking innovations from its Pharma and Nutrition divisions, highlighting key ingredients and formulations designed to support holistic well-being
Pascal Villemagne has announced his intent to step down at the end of March 2025, to take on a new challenge in his professional career.
Akums Drugs & Pharmaceuticals has launched Dapagliflozin + Pioglitazone tablets, a dual-action therapy for diabetes management
Our Q3 FY25 revenue was at Rs. 1,384.1 crore with an EBITDA of Rs. 360 crore resulting in a 26% EBITDA margin
EBITDA rose to Rs. 14.8 crore, marking a 16.5% y-o-y increase, while net profit surged to Rs. 6.4 crore
EBITDA grew by 11% on a YoY basis to Rs. 296 crore due to improved performance in CDMO Sterile Injectables, CRDMO and Generics
Subscribe To Our Newsletter & Stay Updated